Fujifilm Toyama Chemical’s US-based Phase II trial investigating Avigan (favipiravir) in hospitalised Covid-19 patients has recruited 20% of its patient target, with the aim to close enrolment this month, a source said.

On 15 April, the company announced it expanded its manufacturing capacity for Avigan, expecting up to 100,000 treatment courses to be available by July. Read more here.